- Ranolazine 375 mg per tablet
Ranexa is indicated in adults as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies (such as beta-blockers and/or calcium antagonists).
Dosage:
The recommended initial dose of Ranexa is 375 mg twice daily.
After 2–4 weeks, the dose should be titrated to 500 mg twice daily and, according to the patient's response, further titrated to a recommended maximum dose of 750 mg twice daily.
If a patient experiences treatment-related adverse events (e.g., dizziness, nausea, or vomiting), down-titration of Ranexa to 500 mg or 375 mg twice daily may be required. If symptoms do not resolve after dose reduction, treatment should be discontinued.
Administration:
Swallow the tablet whole with a glass of water. Do not chew, crush, or split the tablet.
Can be taken with or without food.
Renal Impairment:
Careful dose titration is recommended in patients with mild to moderate renal impairment (creatinine clearance 30–80 ml/min).
Ranexa is contraindicated in patients with severe renal impairment (creatinine clearance <30 ml/min).
Hepatic Impairment:
Careful dose titration is recommended in patients with mild hepatic impairment.
Ranexa is contraindicated in patients with moderate or severe hepatic impairment.
Drug Interactions:
Concomitant administration of potent CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, voriconazole, posaconazole, HIV protease inhibitors, clarithromycin, telithromycin, nefazodone) is contraindicated.
Careful dose titration is recommended in patients treated with moderate CYP3A4 inhibitors (e.g., diltiazem, fluconazole, erythromycin) or P-glycoprotein inhibitors (e.g., verapamil, ciclosporin).
Malaysia
